Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Harvard Bioscience Continues To Expect 2024 Gross Margin Of Approximately 60% And Adjusted EBITDA Margin In The Mid-teens

Author: Benzinga Newsdesk | May 07, 2024 07:06am

For the full year 2024 revenues to be approximately flat versus 2023. Company sees second half growth versus both first half of 2024 and second half of 2023, supported by new product commercializations and expected improvements in China. The company seest 2024 gross margin of approximately 60% and adjusted EBITDA margin in the mid-teens.

Posted In: HBIO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist